Labopharm Inc

DDS-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about DDS-T

Signal
Opinion
Expert
HOLD
HOLD
January 8, 2009
Broke through the 200-day moving average at about $1.50. Looks like the momentum may start to peter out but there is some pretty good support around $1.40. If her broke that, you should Sell.
Labopharm Inc (DDS-T)
January 8, 2009
Broke through the 200-day moving average at about $1.50. Looks like the momentum may start to peter out but there is some pretty good support around $1.40. If her broke that, you should Sell.
Hap (Robert) Sneddon FCSI
Chief Portfolio Manager & Founder, Castlemoore Inc.
Price
$1.830
Owned
Unknown
DON'T BUY
DON'T BUY
December 14, 2007
Has disappointed everyone for a long time. Didn't get approval on their product. Stock has been decimated. Thinks the worst is over, but it will be a long recovery. He was actually Short the stock for a while. If you own, Hold and see what they do, but don't be a buyer.
Labopharm Inc (DDS-T)
December 14, 2007
Has disappointed everyone for a long time. Didn't get approval on their product. Stock has been decimated. Thinks the worst is over, but it will be a long recovery. He was actually Short the stock for a while. If you own, Hold and see what they do, but don't be a buyer.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$1.070
Owned
No
SELL
SELL
November 15, 2007
Has been a major disappointment. Guided that approvals would be fairly easy to receive, which didn't happen. Trials have been okay, not all that inclusive, so there is a lot of uncertainty.
Labopharm Inc (DDS-T)
November 15, 2007
Has been a major disappointment. Guided that approvals would be fairly easy to receive, which didn't happen. Trials have been okay, not all that inclusive, so there is a lot of uncertainty.
Lesley Marks
Vice President & Portfolio Manager, Jones Heward Investment Counsel
Price
$1.230
Owned
No
BUY
BUY
November 6, 2006
Has been doing fairly well recently because they had their European and Canadian approval for their painkiller. Once they get the US of the way, it should be back over the $7 mark.
Labopharm Inc (DDS-T)
November 6, 2006
Has been doing fairly well recently because they had their European and Canadian approval for their painkiller. Once they get the US of the way, it should be back over the $7 mark.
Chyanne Fickes
Vice President of Investments, Stone Funds
Price
$5.560
Owned
Unknown
BUY
BUY
October 2, 2006
It is a small stock. Believes it will be a winner.
Labopharm Inc (DDS-T)
October 2, 2006
It is a small stock. Believes it will be a winner.
Chyanne Fickes
Vice President of Investments, Stone Funds
Price
$5.830
Owned
No
WATCH
WATCH
August 23, 2005
Entering into a licensing/distribution agreement with Purdue Pharma in the US. Did a disatrous financing last year and the stock sold off. This deal was a rabbit pulled out of a hat. The stock will probably flatline for a bit after this deal. Best to see quarter after quarter how revenues kick in.
Labopharm Inc (DDS-T)
August 23, 2005
Entering into a licensing/distribution agreement with Purdue Pharma in the US. Did a disatrous financing last year and the stock sold off. This deal was a rabbit pulled out of a hat. The stock will probably flatline for a bit after this deal. Best to see quarter after quarter how revenues kick in.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$4.890
Owned
No
DON'T BUY
DON'T BUY
January 17, 2005
Received approval in France for its drug tramadol. Has stubbed its toes many times with investors. Large outstanding stock holding (40 Million?) could come out and flood the market.
Labopharm Inc (DDS-T)
January 17, 2005
Received approval in France for its drug tramadol. Has stubbed its toes many times with investors. Large outstanding stock holding (40 Million?) could come out and flood the market.
Andrew McCreath
Senior Portfolio Manager, Sentry Select Capital
Price
$4.170
Owned
No
DON'T BUY
DON'T BUY
January 17, 2005
Drug companies in general scare value investors. Drugs they produce might injure or kill people. Also there's a history of companies suing each other because of infringement on property rights which can tie up a small company like this. Although they got French approval, FDA could be a whole different matter.
Labopharm Inc (DDS-T)
January 17, 2005
Drug companies in general scare value investors. Drugs they produce might injure or kill people. Also there's a history of companies suing each other because of infringement on property rights which can tie up a small company like this. Although they got French approval, FDA could be a whole different matter.
David Baskin
President, Baskin Wealth Management
Price
$4.170
Owned
No
WATCH
WATCH
August 26, 2004
Management is at its risk. If they start in Europe, the stock will improve. Therefore, be cautious.
Labopharm Inc (DDS-T)
August 26, 2004
Management is at its risk. If they start in Europe, the stock will improve. Therefore, be cautious.
Glenn Paradis, BA, CFA
Vice President & Sr Portfolio Manager, Equities, Aegon Capital Management Inc.
Price
$4.030
Owned
Unknown
DON'T BUY
DON'T BUY
May 17, 2004
Did an issue and it was a disaster. Hasn't even come close to where the issue was priced at. Behind schedule as compared to their competitors.
Did an issue and it was a disaster. Hasn't even come close to where the issue was priced at. Behind schedule as compared to their competitors.
Peter Hodson
CEO & Head of Research, 5i Research Inc.
Price
$4.090
Owned
No
DON'T BUY
DON'T BUY
May 29, 2003
Still suffering from a plethora of disappointments from late 2001 and 2002. Will have a challenge moving up from where it is. Prefers others.
Still suffering from a plethora of disappointments from late 2001 and 2002. Will have a challenge moving up from where it is. Prefers others.
Andrew McCreath
Senior Portfolio Manager, Sentry Select Capital
Price
$5.180
Owned
Unknown
DON'T BUY
DON'T BUY
May 17, 2002
Volatile. Too few projects on the go. Risky.
Volatile. Too few projects on the go. Risky.
Bruce Cooper
Portfolio Manager, T.D. Asset
Price
$5.340
Owned
Unknown
DON'T BUY
DON'T BUY
May 2, 2002
Interesting technology. Future is unclear. Risky.
Interesting technology. Future is unclear. Risky.
Bruce Cooper
Portfolio Manager, T.D. Asset
Price
$4.750
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
April 1, 2002
(Was a top pick on Dec 18 down 46%) Still likes. Got hit with the pull out of Aventis, but should be able to get new deals over the next 6 months. Don't buy until they do strike a deal.
Labopharm Inc (DDS-T)
April 1, 2002
(Was a top pick on Dec 18 down 46%) Still likes. Got hit with the pull out of Aventis, but should be able to get new deals over the next 6 months. Don't buy until they do strike a deal.
Glenn Paradis, BA, CFA
Vice President & Sr Portfolio Manager, Equities, Aegon Capital Management Inc.
Price
$5.800
Owned
Unknown
DON'T BUY
DON'T BUY
March 15, 2002
Speculative and risky. In a competitive sector.
Labopharm Inc (DDS-T)
March 15, 2002
Speculative and risky. In a competitive sector.
Jonathen Wellum, B. Comm, B. Sc
Chief Executive Officer, AIC Limited
Price
$5.380
Owned
Unknown
DON'T BUY
DON'T BUY
March 14, 2002
Would have some questions before buying this stock.
Labopharm Inc (DDS-T)
March 14, 2002
Would have some questions before buying this stock.
Robert Floyd
President, R A Floyd Management
Price
$5.000
Owned
Unknown
BUY
BUY
February 18, 2002
Good product. Has risen very fast and will probably pause for a while. Good price for long term.
Labopharm Inc (DDS-T)
February 18, 2002
Good product. Has risen very fast and will probably pause for a while. Good price for long term.
Brendan Kyne
Chairman and Chief Executive Officer, Leeward Hedge Funds Inc
Price
$9.650
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
January 24, 2002
(Was a top pick on Oct 26 up 50%) Still likes.
Labopharm Inc (DDS-T)
January 24, 2002
(Was a top pick on Oct 26 up 50%) Still likes.
Brendan Kyne
Chairman and Chief Executive Officer, Leeward Hedge Funds Inc
Price
$10.450
Owned
Unknown
BUY
BUY
January 17, 2002
Agreat future. Lots of risks involved, but the reward should be good. Just completed 2 big deals.
Labopharm Inc (DDS-T)
January 17, 2002
Agreat future. Lots of risks involved, but the reward should be good. Just completed 2 big deals.
Glenn Paradis, BA, CFA
Vice President & Sr Portfolio Manager, Equities, Aegon Capital Management Inc.
Price
$10.150
Owned
Unknown
BUY WEAKNESS
BUY WEAKNESS
December 28, 2001
No earnings. Buy on a pull back. Speculation.
Labopharm Inc (DDS-T)
December 28, 2001
No earnings. Buy on a pull back. Speculation.
Brian Acker, CA
Chief Executive Officer, President and Chief Inves, Acker Finley Inc.
Price
$10.850
Owned
Unknown
BUY
BUY
December 24, 2001
Moving up well and should continue.
Labopharm Inc (DDS-T)
December 24, 2001
Moving up well and should continue.
Michael Smedley
Exec VP & Chief Investment Officer, Morgan Meighan & Associates
Price
$11.500
Owned
Unknown
TOP PICK
TOP PICK
December 18, 2001
Making good contracts.
Labopharm Inc (DDS-T)
December 18, 2001
Making good contracts.
Glenn Paradis, BA, CFA
Vice President & Sr Portfolio Manager, Equities, Aegon Capital Management Inc.
Price
$10.100
Owned
Unknown
BUY WEAKNESS
BUY WEAKNESS
November 29, 2001
Good partnership. A lot of potential. Pretty high right now.
Labopharm Inc (DDS-T)
November 29, 2001
Good partnership. A lot of potential. Pretty high right now.
Bruce Cooper
Portfolio Manager, T.D. Asset
Price
$9.490
Owned
Unknown
TOP PICK
TOP PICK
November 12, 2001
Good product. New agreement is good.
Labopharm Inc (DDS-T)
November 12, 2001
Good product. New agreement is good.
Brendan Kyne
Chairman and Chief Executive Officer, Leeward Hedge Funds Inc
Price
$7.940
Owned
Unknown
TOP PICK
TOP PICK
October 26, 2001
Raised $40 million in financing. Good agreements.
Labopharm Inc (DDS-T)
October 26, 2001
Raised $40 million in financing. Good agreements.
Brendan Kyne
Chairman and Chief Executive Officer, Leeward Hedge Funds Inc
Price
$7.050
Owned
Unknown
TOP PICK
TOP PICK
October 1, 2001
Has good potential. Low market cap of $160 million. Good mngmnt. Good alliance. Lots of cash.
Labopharm Inc (DDS-T)
October 1, 2001
Has good potential. Low market cap of $160 million. Good mngmnt. Good alliance. Lots of cash.
Brendan Kyne
Chairman and Chief Executive Officer, Leeward Hedge Funds Inc
Price
$6.450
Owned
Unknown
TOP PICK
TOP PICK
September 4, 2001
Good alliances.
Labopharm Inc (DDS-T)
September 4, 2001
Good alliances.
Brendan Kyne
Chairman and Chief Executive Officer, Leeward Hedge Funds Inc
Price
$6.150
Owned
Unknown
TOP PICK
TOP PICK
July 4, 2001
Lots of cash. Good mngmnt.
Lots of cash. Good mngmnt.
Brendan Kyne
Chairman and Chief Executive Officer, Leeward Hedge Funds Inc
Price
$6.120
Owned
Unknown
Showing 1 to 28 of 28 entries
  • «
  • 1
  • »